The AVIGNA group has developed a proprietary Novel Drug Delivery Platform (NDDP) and has filed for both “composition of matter” and “method of use” patents. Utilizing this proprietary technology, AVIGNA will develop and commercialize improved formulations of existing (Generic and non Generic) drug products. These new formulations can potentially be launched in the US under the 505(b)(2) regulatory pathway.

This development process is driven by a team of dedicated scientists and the resultant products are expected to be filed under the auspices of AVIGNA CHEMITECH PVT LTD and AVIGNA PHARMACEUTICALS LLC (APL).
APL is privately owned by Dr Francis Pinto and Ram.